Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $6.42 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.